| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Liriopesides B targets multiple pathways involved in oxidative stress, inflammation, and cancer. Its antioxidant activity involves scavenging free radicals and reducing oxidative stress. Its anticancer activity involves inducing apoptosis in various cancer cell lines, including non-small cell lung cancer (NSCLC) and ovarian cancer cells. The compound significantly increases apoptotic rates in H460 and H1975 NSCLC cells. Its anti-inflammatory effects involve modulation of immune responses.
|
|---|---|
| ln Vitro |
Liriopesides B, also known as nolinospiroside F, stimulate SIRT1 [1].
In vitro studies demonstrate that Liriopesides B shows obvious antioxidant and bacteriostatic activities. It exhibits potential anticancer activity against human ovarian cancer A2780 cells. The compound induces apoptosis in various cancer cell lines, including NSCLC cells (H460 and H1975), significantly increasing apoptotic rates. Its anti-inflammatory effects have also been reported. The compound's in vitro activity is assessed using cell viability assays, apoptosis assays, and antioxidant assays. |
| ln Vivo |
In vivo activity of Liriopesides B has not been extensively characterized in the available literature. As a steroidal saponin with antioxidant, anti-inflammatory, and anticancer properties, the compound has potential therapeutic applications. However, detailed in vivo efficacy data are not extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro assays for Liriopesides B involve measuring its antioxidant, antibacterial, and anticancer activities. Antioxidant activity is assessed using DPPH, ABTS, or ORAC assays. Antibacterial activity is assessed using standard broth microdilution methods to determine minimum inhibitory concentrations (MIC). Anticancer activity is assessed using cell viability assays (e.g., MTT, SRB) in cancer cell lines such as A2780, H460, and H1975.
|
| Cell Assay |
Cellular assays for Liriopesides B are conducted to evaluate its anticancer and anti-inflammatory effects. Cancer cells (e.g., A2780, H460, H1975) are treated with varying concentrations of the compound for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or SRB assays. Apoptosis is evaluated by Annexin V/PI staining, caspase-3/7 activity, or TUNEL assays. Anti-inflammatory effects are assessed in immune cells by measuring cytokine production. Cell cycle analysis is performed by flow cytometry.
|
| Animal Protocol |
In vivo animal studies for Liriopesides B are limited. For anticancer studies, xenograft models using human cancer cell lines (e.g., A2780, H460) could be employed. Tumor-bearing mice would be treated with the compound via intraperitoneal or oral administration at various doses. Tumor volume would be measured regularly, and body weight monitored for tolerability. At study termination, tumors would be analyzed for apoptosis markers and proliferation markers. However, specific in vivo study protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Liriopesides B have not been extensively characterized. The compound has a molecular weight of 722.90 and a molecular formula of C3₉H₆2O12. The compound is a steroidal saponin with high molecular weight and multiple sugar moieties, which may limit oral bioavailability. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Liriopesides B are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for activity studies. The compound is derived from Liriope species and Ophiopogon japonicus, plants used in traditional medicine with generally favorable safety profiles. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Liriopesides B is a steroidal saponin from Liriope and Ophiopogon species with antioxidant, antibacterial, and anticancer activities. It induces apoptosis in NSCLC and ovarian cancer cells. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity and is typically stored at -20degC.
|
| Molecular Formula |
C39H62O12
|
|---|---|
| Molecular Weight |
722.9024
|
| Exact Mass |
722.424
|
| CAS # |
87425-34-1
|
| PubChem CID |
21630160
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
823.3±65.0 °C at 760 mmHg
|
| Flash Point |
451.7±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
5.42
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
51
|
| Complexity |
1330
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
C[C@]12CC[C@@H]3[C@@]4(C(=CC[C@H]3[C@@H]1C[C@@H]1O[C@@]3(OC[C@@H](C)CC3)[C@H]([C@H]21)C)C[C@@H](O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C[C@H]4O[C@@H]1O[C@H](C)[C@H](O)[C@H](O)[C@H]1O)C
|
| InChi Key |
RMIQIULKBBCLIL-KJXSMTROSA-N
|
| InChi Code |
InChI=1S/C39H62O12/c1-17-9-12-39(46-16-17)18(2)28-26(51-39)15-25-23-8-7-21-13-22(49-35-33(44)31(42)29(40)19(3)47-35)14-27(38(21,6)24(23)10-11-37(25,28)5)50-36-34(45)32(43)30(41)20(4)48-36/h7,17-20,22-36,40-45H,8-16H2,1-6H3/t17-,18-,19-,20+,22+,23+,24-,25-,26-,27+,28-,29-,30-,31+,32-,33+,34+,35-,36-,37-,38-,39+/m0/s1
|
| Chemical Name |
(2S,3R,4R,5R,6R)-2-methyl-6-[(1S,2S,4S,5'S,6R,7S,8R,9S,12S,13R,14R,16R)-5',7,9,13-tetramethyl-14-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~138.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3833 mL | 6.9166 mL | 13.8332 mL | |
| 5 mM | 0.2767 mL | 1.3833 mL | 2.7666 mL | |
| 10 mM | 0.1383 mL | 0.6917 mL | 1.3833 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
